NewAmsterdam Pharma Reports Q1 Revenue and Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy NAMS?
Source: seekingalpha
- Revenue Performance: NewAmsterdam Pharma reported Q1 2026 revenue of $3.04 million, indicating growth; however, this increase has not reversed the overall financial situation.
- Widening Net Loss: The net loss for the quarter ended March 31, 2026, was $48.4 million, significantly up from $39.5 million in the same period of 2025, reflecting increased financial pressure on the company.
- Financial Composition Analysis: The increase in losses is attributed to interest income, non-cash gains related to changes in the fair value of derivative warrant liabilities, and foreign exchange losses, highlighting multiple financial challenges faced by the company.
- Market Risk Assessment: Despite the financial losses, analysts still consider NewAmsterdam Pharma a risk-on buy, indicating ongoing market confidence in its future potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NAMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NAMS
Wall Street analysts forecast NAMS stock price to rise
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 34.850
Low
37.00
Averages
48.63
High
60.00
Current: 34.850
Low
37.00
Averages
48.63
High
60.00
About NAMS
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NewAmsterdam Pharma Reports Q1 Revenue and Losses
- Revenue Performance: NewAmsterdam Pharma reported Q1 2026 revenue of $3.04 million, indicating growth; however, this increase has not reversed the overall financial situation.
- Widening Net Loss: The net loss for the quarter ended March 31, 2026, was $48.4 million, significantly up from $39.5 million in the same period of 2025, reflecting increased financial pressure on the company.
- Financial Composition Analysis: The increase in losses is attributed to interest income, non-cash gains related to changes in the fair value of derivative warrant liabilities, and foreign exchange losses, highlighting multiple financial challenges faced by the company.
- Market Risk Assessment: Despite the financial losses, analysts still consider NewAmsterdam Pharma a risk-on buy, indicating ongoing market confidence in its future potential.
See More
NEWAMSTERDAM PHARMA ANNOUNCES INDUCEMENT GRANTS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4)
Inducement Grants: The Amsterdam Pharma reports on the availability of inducement grants aimed at supporting companies listed under NASDAQ.
Listing Rule 5635(c): The article discusses the implications of NASDAQ Listing Rule 5635(c) concerning inducement grants for companies seeking to attract talent.
See More
NewAmsterdam Pharma Grants Stock Options to New Hires
- Stock Options Granted: NewAmsterdam Pharma's Compensation Committee approved the grant of 15,000 stock options to two non-executive new hires, with an exercise price of $32.81 per share, reflecting the market closing price on April 1, 2026, aimed at attracting talent and enhancing the company's competitive edge.
- Restricted Stock Units: Additionally, the board approved the grant of 3,200 restricted stock units to the same new hires under the 2024 Inducement Plan, further enhancing the company's appeal in the biopharmaceutical sector.
- Vesting Schedule for Options: The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly, ensuring employee stability during their tenure and promoting long-term team development.
- Vesting Schedule for RSUs: The restricted stock units will vest over three years, with one-third vesting each year, designed to enhance employee loyalty and motivation through long-term incentives, thereby driving innovation in cardiovascular disease treatments.
See More
NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)
Inducement Grants: Amsterdam Pharma reports on the availability of inducement grants aimed at supporting companies listed under NASDAQ.
NASDAQ Listing Rule 5635(c)(4): The article discusses the specific NASDAQ listing rule that governs the issuance of inducement grants to attract and retain talent.
See More
NewAmsterdam Pharma Releases FY 2025 Financial Results
- Annual Revenue Performance: NewAmsterdam Pharma reported FY 2025 revenue of $22.5 million, indicating growth; however, the overall financial situation remains challenging, reflecting competitive pressures in the market.
- Net Loss Improvement: The net loss for 2025 was $203.8 million, an improvement from $241.6 million in 2024, suggesting progress in cost control and operational efficiency.
- Cash Flow Status: As of December 31, 2025, NewAmsterdam's cash, cash equivalents, and marketable securities totaled $728.9 million, down from $834.2 million in 2024, indicating pressure on the company's financial management.
- Market Outlook Analysis: Despite improvements in financial data, ongoing net losses and declining cash flow may affect investor confidence, necessitating effective strategies from NewAmsterdam to enhance market competitiveness and financial health.
See More
NewAmsterdam Pharma Reports Clinical Progress and Financial Update
- Regulatory Approval Progress: NewAmsterdam Pharma's Marketing Authorization Applications for obicetrapib and its fixed-dose combination with ezetimibe have been accepted by EMA, UK, and Swiss regulators, with approval decisions expected in the second half of 2026, laying the groundwork for market entry in the cardiovascular disease sector.
- Clinical Trial Data: Topline data from the RUBENS Phase 3 trial is anticipated by the end of 2026, evaluating the efficacy of obicetrapib in patients with type 2 diabetes and metabolic syndrome requiring further LDL-C reduction, which could enhance the company's competitive position in the cardiovascular drug market.
- Strong Financial Position: As of December 31, 2025, NewAmsterdam reported $728.9 million in cash, cash equivalents, and marketable securities, a decrease from 2024, yet sufficient to fund operations through the PREVAIL trial readout and potential U.S. market launch.
- R&D Expense Changes: R&D expenses for 2025 were $141.8 million, down from $151.4 million in 2024, primarily due to the completion of several Phase 3 clinical trials, indicating effective cost control and resource optimization by the company.
See More
NewAmsterdam Pharma Reports Q1 Revenue and Losses
- Revenue Performance: NewAmsterdam Pharma reported Q1 2026 revenue of $3.04 million, indicating growth; however, this increase has not reversed the overall financial situation.
- Widening Net Loss: The net loss for the quarter ended March 31, 2026, was $48.4 million, significantly up from $39.5 million in the same period of 2025, reflecting increased financial pressure on the company.
- Financial Composition Analysis: The increase in losses is attributed to interest income, non-cash gains related to changes in the fair value of derivative warrant liabilities, and foreign exchange losses, highlighting multiple financial challenges faced by the company.
- Market Risk Assessment: Despite the financial losses, analysts still consider NewAmsterdam Pharma a risk-on buy, indicating ongoing market confidence in its future potential.
See More
NEWAMSTERDAM PHARMA ANNOUNCES INDUCEMENT GRANTS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4)
Inducement Grants: The Amsterdam Pharma reports on the availability of inducement grants aimed at supporting companies listed under NASDAQ.
Listing Rule 5635(c): The article discusses the implications of NASDAQ Listing Rule 5635(c) concerning inducement grants for companies seeking to attract talent.
See More
NewAmsterdam Pharma Grants Stock Options to New Hires
- Stock Options Granted: NewAmsterdam Pharma's Compensation Committee approved the grant of 15,000 stock options to two non-executive new hires, with an exercise price of $32.81 per share, reflecting the market closing price on April 1, 2026, aimed at attracting talent and enhancing the company's competitive edge.
- Restricted Stock Units: Additionally, the board approved the grant of 3,200 restricted stock units to the same new hires under the 2024 Inducement Plan, further enhancing the company's appeal in the biopharmaceutical sector.
- Vesting Schedule for Options: The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly, ensuring employee stability during their tenure and promoting long-term team development.
- Vesting Schedule for RSUs: The restricted stock units will vest over three years, with one-third vesting each year, designed to enhance employee loyalty and motivation through long-term incentives, thereby driving innovation in cardiovascular disease treatments.
See More
NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)
Inducement Grants: Amsterdam Pharma reports on the availability of inducement grants aimed at supporting companies listed under NASDAQ.
NASDAQ Listing Rule 5635(c)(4): The article discusses the specific NASDAQ listing rule that governs the issuance of inducement grants to attract and retain talent.
See More
NewAmsterdam Pharma Releases FY 2025 Financial Results
- Annual Revenue Performance: NewAmsterdam Pharma reported FY 2025 revenue of $22.5 million, indicating growth; however, the overall financial situation remains challenging, reflecting competitive pressures in the market.
- Net Loss Improvement: The net loss for 2025 was $203.8 million, an improvement from $241.6 million in 2024, suggesting progress in cost control and operational efficiency.
- Cash Flow Status: As of December 31, 2025, NewAmsterdam's cash, cash equivalents, and marketable securities totaled $728.9 million, down from $834.2 million in 2024, indicating pressure on the company's financial management.
- Market Outlook Analysis: Despite improvements in financial data, ongoing net losses and declining cash flow may affect investor confidence, necessitating effective strategies from NewAmsterdam to enhance market competitiveness and financial health.
See More
NewAmsterdam Pharma Reports Clinical Progress and Financial Update
- Regulatory Approval Progress: NewAmsterdam Pharma's Marketing Authorization Applications for obicetrapib and its fixed-dose combination with ezetimibe have been accepted by EMA, UK, and Swiss regulators, with approval decisions expected in the second half of 2026, laying the groundwork for market entry in the cardiovascular disease sector.
- Clinical Trial Data: Topline data from the RUBENS Phase 3 trial is anticipated by the end of 2026, evaluating the efficacy of obicetrapib in patients with type 2 diabetes and metabolic syndrome requiring further LDL-C reduction, which could enhance the company's competitive position in the cardiovascular drug market.
- Strong Financial Position: As of December 31, 2025, NewAmsterdam reported $728.9 million in cash, cash equivalents, and marketable securities, a decrease from 2024, yet sufficient to fund operations through the PREVAIL trial readout and potential U.S. market launch.
- R&D Expense Changes: R&D expenses for 2025 were $141.8 million, down from $151.4 million in 2024, primarily due to the completion of several Phase 3 clinical trials, indicating effective cost control and resource optimization by the company.
See More
